MedPath

Yangtze River Pharmaceutical (Group) Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:3

Trial Phases

3 Phases

Phase 1:2
Phase 3:1
Phase 4:1

Drug Approvals

2

PHILIPPINES:2

Drug Approvals

Aepanpraz

Approval Date
Jul 14, 2025
PHILIPPINES

Sefozin

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 3
1 (25.0%)
Phase 4
1 (25.0%)

Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery

Phase 3
Completed
Conditions
Participants With Acute Moderate to Severe Pain Following Abdominal Surgery
Interventions
First Posted Date
2025-04-01
Last Posted Date
2025-04-01
Lead Sponsor
Yangtze River Pharmaceutical Group Co., Ltd.
Target Recruit Count
224
Registration Number
NCT06904248
Locations
🇨🇳

Cangzhou People's Hospital, Cangzhou, China

🇨🇳

The Third Xiangya Hospital Of Central South University, Changsha, China

🇨🇳

Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China

and more 15 locations

Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects

Phase 1
Completed
Conditions
Pain
Interventions
Drug: Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)
Drug: Meloxicam Nanocrystal Injection (ANJESO®)
First Posted Date
2025-03-30
Last Posted Date
2025-03-30
Lead Sponsor
Yangtze River Pharmaceutical Group Co., Ltd.
Target Recruit Count
20
Registration Number
NCT06902090
Locations
🇨🇳

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery

Phase 4
Recruiting
Conditions
Postoperative Pain
Rehabilitation
Interventions
First Posted Date
2024-06-03
Last Posted Date
2024-06-03
Lead Sponsor
Yangtze River Pharmaceutical Group Co., Ltd.
Target Recruit Count
210
Registration Number
NCT06439368
Locations
🇨🇳

Nanfang Hospital of Southern Medical University, Guangzhou, Guangzhou, China

A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol

Phase 1
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Tunodafil Hydrochloride Tablets
Drug: Placebo
Other: Alcohol
First Posted Date
2023-08-04
Last Posted Date
2023-08-04
Lead Sponsor
Yangtze River Pharmaceutical Group Co., Ltd.
Target Recruit Count
22
Registration Number
NCT05976503
Locations
🇨🇳

Peking University People's Hospital, Peking, China

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.